• 최종편집 2024-06-02(일)

Animal Rights
Home >  Animal Rights

실시간뉴스
  • 농림축산식품부, 제1회 반려동물행동지도사 자격시험 시행
    2급 반려동물행동지도사 자격시험 [GEN - 주한외국기업뉴스] 농림축산식품부는 올해 새로 시행되는 반려동물행동지도사 자격시험 응시에 필요한 사항을 공고하고 제1회 시험을 시행할 계획이라고 밝혔다. 공고의 주요 내용은 ① 시험일정 및 응시원서 접수 방법, ② 시험과목 및 시험방법, ③ 응시자격, ④ 증빙자료, ⑤ 응시수수료 납부방법, ⑥ 응시자 유의사항 등이다. 반려동물행동지도사 1차 필기시험은 8월 24일에 시행되며, 2차 실기시험은 10~11월 중(추후 공지)으로 시행될 예정이다. 시험 응시를 희망하는 경우 이번 공고를 통해 안내한 일정에 따라 6월 24일부터 7월12일에 걸쳐 응시원서를 접수할 수 있다. 시험은 1차 및 2차 시험으로 구성되며, 1차 필기시험은 반려동물 행동학 등 5개 과목에 대해 선택형으로 시행된다. 2차 실기시험은 응시자 본인 또는 직계가족 소유 6개월령 이상의 반려동물과 동행하여 반려동물 기본 지도능력을 평가한다. 올해는 2급 시험만 시행되며, 2급 시험의 응시자격은 18세 이상이다. 증빙자료, 응시자 유의사항 등 공고 및 원서접수에 대한 사항은 반려동물행동지도사 자격정보시스템을 통해 확인할 수 있으며, 시험 공고는 농식품부 누리집, 농림수산식품교육문화정보원 누리집을 통해서도 확인할 수 있다.
    • Animal Rights
    • Animal Right
    2024-05-26
  • Evonik Korea establishes strategic partnership with CARIMA and BREEZM
    Evonik Korea establishes strategic partnership with CARIMA and BREEZM     Evonik Korea, CARIMA and BREEZM signed a Memorandum of Understanding(MoU) for strategic cooperation in Seoul, Korea. Mr. Thomas Choi, Korea Cluster Head, Mr. Kwangmin Kim, Vice President of CARIMA and Mr. Wooseok Sung, President of BREEZM, signed the relevant documents on behalf of the three parties. According to MoU, Evonik Korea will deepen cooperation and continue developing proper photopolymer resins. Furthermore, it will be a momentum to speed up the development of DLP 3D printing technology including photopolymer resins.    
    • Animal Rights
    2023-05-10
  • 산업계 및 NGO 단체, 동물대체시험 협력조직(ICCS) 설립
    한국무역협회     전 세계 35 개 이상의 화장품 제조업체, 산업 단체 및 동물보호단체는 동물대체시험(비동물시험) 촉진을 목적으로 하는 ‘화장품안전국제협력(International Collaboration on Cosmetics Safety, ICCS)‘ 조직을 설립했다. 뉴욕에 사무소를 두고 있는 글로벌이니셔티브 ICCS 는 화장품, 퍼스널케어 및 그 성분에 대한 동물대체 안전성평가 채택을 위해 자금을 지원하며, 동물대체시험 가속화를 위한 규제기관에 대한 압력이 증가하는 가운데 설립됐다. 2월 8일 발표된 ICCS 의 목표는 아래와 같다. - 비동물시험 안전성 평가방법 평가 및 개발 - 평가결과 규제기관과 공유 - 비동물시험의 채택 가속화를 위한 산업계 교육 및 훈련 제공 유럽화장품협회(Cosmetics Europe)에 따르면, 이미 많은 프로젝트가 ICCS 를 통해 진행되고 있으며, 최근 미국은 개인위생용품에 대한 대부분의 동물실험을 단계적으로 중단하는 의회 권고 및 화장품 법안이 채택된 바 있다. 캐나다 정부 또한 신규물질에 대한 동물실험을 줄이기 위한 규제 개정을 검토하고 있으며, 캐나다화장품협회(Cosmetics Alliance Canada, CAC)는 2023년 동물대체세계대회(Animal Alternatives World Congress)를 개최할 예정이다. [출처: Chemical Watch]
    • Animal Rights
    • Animal Right
    2023-02-19
  • 하천 내 반려동물 운동·휴식 편의시설 설치 하천법 일부개정법률안 대표발의
        더불어민주당 김회재 의원(전남 여수시을)은 13일 하천 내 반려동물 편의시설을 설치할 수 있도록 하는 내용의 '하천법 일부개정법률안'을 대표 발의했다. 현행법 상 하천구역에서 가축을 방목·사육하는 행위는 금지되어 있다. 그러나 반려동물 가구가 늘어남에 따라 반려동물과 함께 하천을 이용하는 사례가 많아, 이들을 위한 별도의 휴식 등 편의시설이 필요하다는 지적이다. 이에 김 의원은 개정안을 통해 하천구역 내 반려동물 운동·휴식시설을 설치할 수 있도록 규제 조항을 일부 완화했다. 또한 이용 급증에 따라 발생할 환경 오염을 예방하기 위해 오염 실태 주기적 검사, 오염 우려지역 조치 명령 등도 개정안에 포함했다. 국무조정실은 올해 2월 규제개혁신문고에 접수된 국민 건의 중 하천 내 소규모 반려동물 놀이터 등 설치를 대표 사례로 선정해, 2022년까지 법 개정을 추진하겠다 밝힌 바 있다. 김회재 의원은 “반려동물 천만 시대에 많은 시민이 반려동물과 함께 생활하고 있다. 시민과 함께하는 반려동물도 불편함이 없도록 규제를 완화할 필요가 있다”고 지적했다.
    • Animal Rights
    • Animal Right
    2022-05-13
  • '개 식용 문제 논의를 위한 위원회' 운영 연장
               '개 식용 문제 논의를 위한 위원회'는 2021년 12월 9일 출범 후 4월 현재까지 개 식용 문제 해결을 위한 논의를 진행해 왔다.   그동안 활발한 논의를 통하여 개 식용 종식이 시대적 흐름이라는 인식에 공감대를 이루는 성과가 있었으나 아직 합의에는 이르지 못해, 추가적인 논의를 위해 위원회 운영을 2개월 연장하기로 결정하였다.   위원회는 운영 초기부터 개 식용 문제에 대해 이해관계자 등 참여자들 간에 입장 차이가 커서 상호 이해의 폭을 넓히는 것에 중점을 두어 운영하였다.   이에 따라 개 식용 문제 논의에 활용하기 위해 식용 목적 개 사육 현황 등을 조사했으며, 이는 식용 목적 개 관련 통계 자료가 없었던 상황에서 정부가 처음으로 조사했다는 의미가 있다. 또한 개 식용 관련 국민의 인식을 알아보기 위한 설문조사를 실시하였다.   한편 갈등관리 전문기관을 통해 참여 위원과 관련 업계 종사자 등에 대한 심층면접을 실시하여 종식시기, 지원방안 등 그들의 관심 사항과 대립되는 입장을 정확히 진단하여 갈등을 해결하기 위해 노력하였다.     아울러 대만의 개 식용 종식 관련 현지 전문가와 국제 화상회의를 통해 ‘대만의 종식 사례’를 파악하는 등 공감의 폭을 넓혔으며, 이외에도 ‘개 식용 관련 위생적 문제점’, ‘현행법 체계’ 등에 대한 전문가 발표와 논의를 통해 개 식용과 관련한 현 상황을 진단하고 이해를 도모하였다.   참고로 정부는 2021년 11월 25일 국무총리 주재로 ‘국정현안점검조정회의’를 개최하여 '개 식용 문제에 대한 사회적 논의 추진 방향'을 논의하였으며, 그 결과 사회적 논의기구를 관련 동물보호단체, 육견업계, 전문가, 정부 인사 등 21명으로 구성하여 개 식용 문제를 논의하기로 한 바 있다.   정광호 위원장은 "위원회 운영의 기본 원칙인 합의 정신을 실현하기 위해 육견업계와 동물보호단체 등의 입장을 발표할 수 있는 기회를 부여하는 등 충분한 시간을 가지고 논의하는 방식으로 위원회를 운영했으며, 개 식용 종식이 시대적 흐름이라는 인식을 같이하는 성과를 거두었다”라고 강조하면서, "앞으로 그동안 쌓은 위원 간 신뢰와 공감대를 바탕으로 대타협을 도출하기 위해 최선을 다하겠다”라고 밝혔다.
    • Animal Rights
    • Animal Right
    2022-05-06
  • Safety is SKC Evonik Peroxide Korea’s best value.
    Safety is SKC Evonik Peroxide Korea’s best value.     SKC Evonik Peroxide Korea Co., Ltd. (SEPK) in Ulsan Petrochemical Industrial Complex, has achieved 15 times of accident-free goal.  SEPK, maintaining a stable growth in the domestic peroxide industry, declared the start of accident-free goal on December 12, 2003. With the declaration, it has emphasized that safety is the highest value that pursues the sustainable growth of the company and the happiness within the employee’s family. Then by encouraging voluntary participation and activeness of every employee, 15 times of accident-free goal have been achieved on February 19, 2022.   During that period, SEPK has successfully implemented large and various projects such as the triple increase in production capacity with stable operation. SEPK as the sole supplier of the peroxide applicable to HPPO (Hydrogen Peroxide Propylene Oxide) in the country, produces and supplies diverse products including the electronic grade peroxide home and abroad.    Thomas Choi, Representative Director of SEPK, said that Evonik Industries AG, the parent company of SEPK, is operating the system of Evonik Safety Award to ensure accident-free and SEPK won Evonik Emerald Safety Award zero loss time injuries for 25 years) for being accident-free until 2018 after the start-up of the plant in 1993.    Thus, the accident-free goal along with such company safety system has been instrumental in embedding a safety culture in employees and the way of daily life. Choi also added that employees have a strong will to reverify that they are the leader in the peroxide industry based on strong safety by winning Evonik Ruby Safety Award (zero loss time injuries for 30 years) in the near term in December 2023 and achieving 20 times of accident-free goal in November 2028.
    • Animal Rights
    2022-04-12

실시간 Animal Rights 기사

  • [단독외신] Facebook’s Oculus Quest 2 was preordered five times more than predecessor
    [단독외신] Facebook’s Oculus Quest 2 was preordered five times more than predecessor Mark Zuckerberg using an Oculus VR headset.AFP via Getty Images Facebook’s virtual reality ambitions are finally catching on with consumers. The company’s latest VR headset, the Oculus Quest 2, has received five times as many preorders as its 2019 predecessor, Mark Zuckerberg confirmed on the company’s Thursday earnings call, saying the device’s reception has “surpassed our expectations.” The Quest 2, which at $299 costs $100 less than the original and includes a faster processor, more lightweight design and has a more high definition display, began shipping to customers earlier this month. “I think that the new Quest 2 product is extraordinary, I love using it,” Zuckerberg said. “I’m really proud of the work that we’ve done there.” Facebook shares were down more than 6 percent on Friday, however, as the company also revealed that its active user numbers in the US and Canada had dipped slightly in the quarter. Other than slightly lower user numbers in its key market, Facebook beat earnings estimates across the board, including better-than-expected ad revenue boosted by spending returning following a second quarter slowdown. Facebook beat revenue expectations by 80 cents, bringing in $2.71 per share versus the forecasted $1.91. The Menlo Park, Calif.-based company also raked in revenue of $21.5 billion, up 22 percent year-over-year and well ahead of the expected $19.8 billion.
    • Animal Rights
    2020-10-31
  • [단독외신] Hypera Pharma Switches to Rimini Street Support for Its SAP Applications
    Hypera Pharma Switches to Rimini Street Support for Its SAP Applications Hypera Pharma Switches to Rimini Street Support for its SAP Applications Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Hypera Pharma, Brazil’s largest pharmaceutical company, has switched from SAP to Rimini Street Support for its highly customized SAP ECC 6.0 applications, Microsoft SQL Server Database and SAP BusinessObjects software. The company also switched from SAP’s Solution Manager to Rimini Street Watch for SAP, ensuring seamless monitoring for its SAP systems. By switching to Rimini Street Support, Hypera Pharma was able to leverage its significant support savings to fund the company’s business transformation priorities, including expanding the corporate pharmaceutical brand and funding cutting-edge pharmaceutical research and development (R&D) with Hynova, the company’s modern research center in Brazil.Procurement Drives Innovation by Partnering with IT And Business LeadersBased in São Paulo, Hypera Pharma produces popular medicine brands used by over 200 million Brazilians, along with vitamins, nutritional supplements and dermo cosmetics. At the end of 2017, the company announced a new corporate brand with an exclusive focus on the pharmaceutical sector, a competitive industry that demands high investments in innovation and R&D, along with increasing capacity to launch new products and medicines to its consumers more often. This new business direction sparked Hypera Pharma’s leaders to reinvent its operations, realign business priorities and seek out initiatives to drive cost optimization.The decision to move to Rimini Street Support was spearheaded by Hypera Pharma’s heads of procurement and IT, who were tasked with optimizing resources and saw the opportunity to reduce the spending for the company’s high SAP maintenance and support costs and at the same time improve support service. They worked closely to create a business case to demonstrate to the company’s CEO that switching to third-party support would bring security, operational efficiency and savings. The company’s heads of procurement and IT determined that Hypera Pharma should not be locked into the vendor’s time-bound upgrade path to S/4HANA as it did not make sense for the business in the short term. They found little value and no ROI in making this highly disruptive move when their current customized ERP system perfectly met their business needs.“Procurement leaders should feel empowered to bring ideas to company leaders on how their organization can be more strategic and align with business priorities. They can influence decision-makers on how IT initiatives, such as adopting third-party support, adds value and frees up resources for other important projects and innovation,” said Humberto Guimaraes, head of procurement, Hypera Pharma. “Switching to Rimini Street Support is part of a new mindset that has enabled the company to be more relevant in the pharmaceutical industry. With our support savings, we can increase investments across the business, including product R&D, digitalization, process automation and new ERP applications that modernize logistics operations and allow product traceability.”Ultra-Responsive Support with Industry-Leading SLAsHypera Pharma, along with all Rimini Street clients, benefits from the Company’s flexible, premium-level enterprise software support model, including its industry-leading Service Level Agreement (SLA) of 10-minute response times for all critical Priority 1 cases. Clients are also assigned a Primary Support Engineer, backed by a team of functional and technical experts with an average of 15 years’ experience in the client’s specific enterprise software system. Hypera Pharma was using some components of SAP Solution Manager, but working with Rimini Street’s Proactive Support Services team, the company instead implemented Rimini Street Watch for SAP. The solution combines proactive diagnostics and web-based dashboards to help Hypera Pharma identify and mitigate issues before they become critical.“Maintaining our ERP support with SAP meant staying in the comfort zone. Rimini Street showed that the change to third-party support is worthwhile. Now we have reduced our SAP maintenance and support costs, allowing those resources to be directed towards our current business goals. We no longer worry about our ERP support since switching to Rimini Street,” continued Guimaraes.“Modern companies in the digital era like Hypera Pharma, who want to maintain a leadership position in the market, need to optimize their IT costs and find resources to invest in innovation and business transformation,” said Edenize Maron, general manager, Latin America, Rimini Street. “The company’s heads of procurement and IT spearheaded the change to third-party support to generate cost savings that contributed to the organization’s strategic business goals, including modernizing logistics and accelerating R&D to bring products to market quicker. This demonstrates how key it is that all company leaders participate in supporting growth and innovation.”
    • Animal Rights
    2020-10-21
  • [단독외신] Microsoft defends diversity efforts after feds allege discrimination
    [단독외신] Microsoft defends diversity efforts after feds allege discrimination Getty Images Microsoft stood by its efforts to hire and promote more black staffers this week after the feds raised concerns that it was making discriminatory employment decisions. The US Department of Labor took issue with Microsoft’s June pledge to double its number of black and African American managers and other leaders by 2025, warning the tech giant in a letter that it’s forbidden as a federal contractor from discriminating against workers because of their race. The Sept. 29 letter also asked Microsoft to submit records proving it’s not making illegal race-based hiring decisions — an allegation the company said it “emphatically” denies. “We hire and promote the most qualified person. And nothing we announced in June changes that,” Dev Stahlkopf, Microsoft’s corporate vice president and general counsel, said in a blog post Tuesday. “Instead, our continued focus is to work hard to consider and develop the broadest range of qualified candidates for opportunities.” Microsoft was among several large companies that announced effort this summer to address racism and promote opportunities for black people amid massive protests sparked by the police killing of George Floyd. In a June 23 message announcing Microsoft’s initiatives, CEO Satya Nadella said the company would expand leadership development programs for midlevel black employees and pair higher-ranking black staffers with mentors to help them climb the corporate ladder. But the Labor Department’s Office of Federal Contract Compliance Programs indicated Microsoft’s plans may run afoul of the government’s guidelines for promoting diversity in hiring. Officials set an Oct. 29 deadline for the company to submit documents related to its efforts to help black employees. “This statement by the CEO did not reference any established goals in an affirmative action program, and appears to imply that employment action may be taken based on race,” office director Craig Leen wrote in the letter, which the feds provided to The Post. While federal contractors are supposed to set goals for recruiting minorities and women based on availability, “contractors must not engage in discriminatory practices in meeting these goals,” Leen said. Microsoft is confident that its diversity efforts comply with all federal employment laws, Stahlkopf said. The company will provide the Labor Department with the information it requested and defend its approach if needed, he said. “We look forward to helping the [Office of Federal Contract Compliance Programs] understand the legality of our programs as we work towards a shared goal of promoting diversity in full conformity with federal law,” Stahlkopf said.
    • Animal Rights
    2020-10-08
  • [단독외신] Eli Lilly seeks emergency use of its antibody drug for COVID-19
    [단독외신] Eli Lilly seeks emergency use of its antibody drug for COVID-19 LightRocket via Getty Images Drugmaker Eli Lilly says it has asked the US government to allow emergency use of its experimental antibody therapy based on early results from a study that suggested the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19. Eli Lilly announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists. Its drug is similar to one that President Trump received on Friday from Regeneron Pharmaceuticals. These medicines supply concentrated versions of specific antibodies to help the immune system clear the coronavirus that causes COVID-19. They’re given as a one-time treatment through an IV. Lilly has already started making one of the two antibodies in its drug, betting that ongoing studies will prove it worthwhile. It’s not clear if the evidence will be viewed as strong enough for the Food and Drug Administration to grant emergency use authorization, as it has done for the antiviral drug remdesivir. The results are an interim look at a mid-stage study in which 112 people received the antibodies and 156 got a placebo. The amount of virus was significantly lower 11 days later in those given the drug — the main goal of the study. Virus also was lower at earlier time points as well. Symptom scores were better at three days. About 5.8 percent of patients given placebo required hospitalization or an emergency room visit versus 0.9 percent of those given the antibodies. The company said there were no serious drug-related side effects.
    • Animal Rights
    2020-10-08
비밀번호 :